MD Anderson Research Highlights for January 26, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current clinical advances include combination therapies for thyroid cancer and multiple myeloma, as well as discoveries to improve CRISPR/Cas9 gene editing, to identify biomarkers for immunotherapy response, to utilize T cell therapy for...
MD Anderson researchers elected as AAAS Fellows
In honor of their notable contributions to the field of cancer research, Juan Fueyo, M.D., and Victor Prieto, M.D., Ph.D., from The University...
MD Anderson and Yingli Pharma initiate strategic collaboration to advance development of multiple oncology programs
The University of Texas MD Anderson Cancer Center and Yingli Pharma US, Inc. today announced a strategic alliance to advance several oncology...
Nano-sized vesicles with ACE2 receptor could prevent, treat infection from current and future strains of SARS-CoV-2
Scientists at The University of Texas MD Anderson Cancer Center and Northwestern Medicine have identified natural extracellular vesicles containing the ACE2 protein (evACE2) in the blood of COVID-19 patients that can block infection from broad strains of SARS-CoV-2 virus in preclinical studies. The study was published today in Nature Communications.
The evACE2 act as decoys in the body and can serve as a therapeutic to be...
MD Anderson and Eisbach Bio announce strategic collaboration to develop medicines targeting epigenetic machinery in oncology
The University of Texas MD Anderson Cancer Center and Eisbach Bio GmbH today announced a strategic research collaboration to jointly discover...
MD Anderson Research Highlights for January 12, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
Blood test helps predict who may benefit from lung cancer screening
A blood test, combined with a risk model based on an individual’s history, more accurately determines who is likely to benefit from lung cancer...
Relatlimab plus nivolumab improves progression-free survival in metastatic melanoma
In patients with untreated, advanced melanoma, the combination of immune checkpoint inhibitors relatlimab and nivolumab doubled the progression-free...